Skip to content

Humanigen’s lenzilumab shows positive effect in COVID-19 in study

September 1, 2020

Results from a 39-patient case-control study in hospitalized COVID-19 patients showed a significant treatment benefit from Humanigen’s (OTCQB:HGEN) lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. The data were just published in Mayo Clinic Proceedings.

12 severely ill patients received lenzilumab and 27 contemporaneous matched control patients, identified from an electronic registry of COVID-19 patients matched for age, sex, disease severity and baseline oxygen requirements, received standard-of-care (SOC) treatment.

The relative risk of invasive mechanical ventilation (IMV) and/or death was reduced 80% in the lenzilumab group. Specifically, the risk of IMV and/or death was 8% in lenzilumab-treated patients compared to 41% in the control group (p=0.07).

Median time to resolution of acute respiratory distress syndrome (ARDS) was one day in lenzilumab patients versus eight days in the control group (p<0.01). Median time to discharge was shorter in the lenzilumab group, five days versus 11 days (p=0.008).

Lenzilumab was also associated with a significant reduction in an inflammatory marker called c-reactive protein and improved lymphocyte counts.

The antibody is currently being evaluated in a Phase 3 NIH study called COVID-19 Big Effect.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: